Oklahomans working to grow the state’s biosciences industry can learn about ways to fund research and advance new discoveries at the 2014 BioSummit on March 26 at the Skirvin Hilton Hotel in Oklahoma City.
Hosted by the Oklahoma Biosciences Association, the BioSummit will feature experts in scientific discovery, commercialization and funding who will share their insights with scientists and entrepreneurs from across the state.
Topics will include funding fundamentals, partners and exit strategies, drug repurposing, positioning for early stage investments and key elements of marketing and interacting with the bio industry.
“We’re pleased to be able to bring together experts in drug discovery, funding and company development for this one-day BioSummit,” said Scott Meacham, CEO of i2E Inc., which manages the Oklahoma Bioscience Association. “Our researchers and bioscience entrepreneurs will benefit greatly from the experiences of those who have been through the drug discovery and commercialization process before.”
Industry experts scheduled to make presentations include William Paiva, managing director of the Oklahoma Life Science Fund; Von Allen, director of development at the University of Oklahoma and the Stephenson Cancer Center; Clayton Duncan, CEO at Accele Biopharma in Oklahoma City; Will Pedranti with Hall Estill law firm; and Chris Yoakim with AstraZenica, among others.
Awards to be given
Following the BioSummit, conference attendees will be joined by other community leaders for the Oklahoma BioScience Awards Dinner. Four awards will be presented to recognize individuals and organizations that have worked to advance the state’s biosciences industry.